Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for IDL Diagnostics AB's Debt-to-EBITDA or its related term are showing as below:
FRA:80R'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.64 Med: -1.25 Max: 4.88
Current: -0.71
During the past 13 years, the highest Debt-to-EBITDA Ratio of IDL Diagnostics AB was 4.88. The lowest was -1.64. And the median was -1.25.
FRA:80R's Debt-to-EBITDA is ranked worse than 100% of 114
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs FRA:80R: -0.71
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
IDL Diagnostics AB Debt-to-EBITDA Related Terms
IDL Diagnostics AB Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for IDL Diagnostics AB's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:80R vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
IDL Diagnostics AB (FRA:80R) has a Debt-to-EBITDA of 2.39 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IDL Diagnostics AB. According to the industry distribution chart, IDL Diagnostics AB ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry.
Is IDL Diagnostics AB's Debt-to-EBITDA too high?
IDL Diagnostics AB's current Debt-to-EBITDA is 2.39. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. IDL Diagnostics AB's value of 2.39 is 3.5% above this industry median. Based on the distribution chart, IDL Diagnostics AB ranks #999999 out of 114 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, IDL Diagnostics AB has a GF Score™ of 54/100, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #999999 out of 114 companies for Debt-to-EBITDA. This places IDL Diagnostics AB in the lower half of its industry. The industry median Debt-to-EBITDA is 2.31. IDL Diagnostics AB's value of 2.39 is 3.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 114 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IDL Diagnostics AB's current Debt-to-EBITDA of 2.39 is 3.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on IDL Diagnostics AB. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IDL Diagnostics AB's current Debt-to-EBITDA is 2.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
IDL Diagnostics AB (FRA:80R) has a current Debt-to-EBITDA of 2.39. The stock's GF Value™ is €0.03, compared to a current price of €0.02 — trading 17.3% below its estimated fair value. The current Debt-to-EBITDA is 2.39 and 3.5% above the Medical Diagnostics & Research industry median of 2.31. IDL Diagnostics AB's overall GF Score™ is 54/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For IDL Diagnostics AB (FRA:80R), the current Debt-to-EBITDA is 2.39 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (FRA:80R) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of €0.02 is trading 17.3% below its estimated GF Value™ of €0.03.
Key valuation signals for FRA:80R:
Debt-to-EBITDA: 2.39
GF Value™: €0.03 vs. price of €0.02 (17.3% below fair value)
Industry Position: 3.5% above the Medical Diagnostics & Research median (#999999 of 114)
No single metric tells the full story. See the FRA:80R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
54GF Score
Get the complete analysis for FRA:80R
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:80R has been successfully added to your 
